title: Conjugated linoleic acid isomers may diminish human macrophages adhesion to endothelial surface.
abstract: Dysfunction of endothelial cells and activation of monocytes in the vascular wall are important pathogenetic factors of atherosclerosis. Conjugated linoleic acids (CLAs) can modulate the function of immune system in humans: reduce the concentration of atherogenic lipoproteins, and the intensity of inflammatory processes in the plasma. In this paper, we focus on macrophage's surface integrins (β1 integrin CD49d/CD29-(VLA4); Mac-1 as well as endothelial human vein endothelial cell (HUVEC) surface adhesins: vascular cell adhesion molecule-1 (VCAM-1) and intracellular cell adhesion molecule-1 (ICAM-1)) expression in relation to CLA isomer used during cell culture. Both CLA isomers decreased expression of VLA-4 and Mac-1 on macrophages compared with control cells (cultured with bovine serum albumine (BSA) or oxidized form of low-density lipoproteins). cis-9, trans-11 CLA isomer reduced ICAM-1 and VCAM-1 expression on the endothelium surface. Strong tendency to reduce of adhesion of macrophages to HUVEC in the cells cultured with CLA isomers was observed. The potential role of cis-9, trans-11 CLA in the reduction of adhesion of macrophages to the HUVEC--one of the important steps in the inflammatory process, can be considerate. These mechanisms may contribute to the potent anti-atherosclerotic effects of CLA in vivo.
authors: Department of Biochemistry and Human Nutrition, Pomeranian Medical University, Szczecin, Poland. ewast@sci.pam.szczecin.pl
authors: Ewa
authors: E
authors: Stachowska
authors: Aldona
authors: A
authors: Siennicka
authors: Magdalena
authors: M
authors: Baśkiewcz-Hałasa
authors: Joanna
authors: J
authors: Bober
authors: Boguslaw
authors: B
authors: Machalinski
authors: Dariusz
authors: D
authors: Chlubek
mesh_terms: D000818:Animals; D050197:Atherosclerosis / Q000378:metabolism / Q000517:prevention & control; D002417:Cattle; D002448:Cell Adhesion; D018929:Cell Culture Techniques; D004041:Dietary Fats / Q000494:pharmacology / Q000627:therapeutic use; D042783:Endothelial Cells / Q000187:drug effects / Q000378:metabolism; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D007249:Inflammation / Q000378:metabolism; D039041:Integrin alpha4beta1 / Q000378:metabolism*; D018799:Intercellular Adhesion Molecule-1 / Q000378:metabolism*; D007536:Isomerism; D019787:Linoleic Acid / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D044243:Linoleic Acids, Conjugated / Q000494:pharmacology* / Q000627:therapeutic use; D008077:Lipoproteins, LDL; D016177:Macrophage-1 Antigen / Q000378:metabolism*; D008264:Macrophages / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D012709:Serum Albumin; D014471:Umbilical Veins; D019010:Vascular Cell Adhesion Molecule-1 / Q000378:metabolism*
chemical_list: D004041:Dietary Fats; D039041:Integrin alpha4beta1; D044243:Linoleic Acids, Conjugated; D008077:Lipoproteins, LDL; D016177:Macrophage-1 Antigen; D012709:Serum Albumin; D019010:Vascular Cell Adhesion Molecule-1; D018799:Intercellular Adhesion Molecule-1; D019787:Linoleic Acid